AUTHORS
Andrew Branagan, MD, PhD, Shayna Sarosiek, MD2, Matthew Lei, PharmD3, Jorge J Castillo, MD4, Jeffrey Matous, MD5, Larry D Anderson Jr, MD, PhD6, Gottfried von Keudell, MD7, Julie Haydu, MD, PhD8, Peter Forsberg, MD9, Camille Edwards, MD10, Tarek Mouhieddine, MD11, Diana D Cirstea, MD12, Benjamin Robert Puliafito, MD13, Andrew J. Yee, MD14, Joshua Gustine, MD, MPH15, Katherine Kacena16, Kirsten Meid, MPH17, Shekina Emongo18, Alberto Guijosa, MD19, Lisette Packer, RN20, Meredith Richardson, RN21, Mollie Furtado, RN22, Emerentia Agyemang, CNP23, Jill N Burke, CNP, DipACLM24, Kelley Grealish25, Kareem Mosaheb26, Alexis Barselau27, Keira Thompson28, Alicia Marggraf29, Nina Budano30, Julia Nguyen31, Alexandra usher, MD32, Nickolas Tsakmaklis33, Shirong Liu, PhD34, Amanda Kofides, MSc35, Maria Luisa Guerrera, MD36, Zachary R Hunter, PhD37, Christopher Patterson, MBA, MPH38, Noopur Raje, MD39, Steven Treon, MD, PhD40
AFFILIATIONS
1 Massachusetts General Hospital, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Massachusetts General Hospital, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Colororado Blood Cancer Institute, Denver, Colorado, United States
6 UT Southwestern Medical Center, Dallas, Texas, United States
7 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
8 Massachusetts General Hospital, Boston, Massachusetts, United States
9 Colororado Blood Cancer Institute, Denver, Colorado, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Massachusetts General Hospital, Boston, Massachusetts, United States
13 Massachusetts General Hospital, Boston, Massachusetts, United States
14 Massachusetts General Hospital, Boston, Massachusetts, United States
15 Massachusetts General Hospital, Boston, Massachusetts, United States
16 Katherine Kacena Consulting, Boston, Massachusetts, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
18 Massachusetts General Hospital, Boston, Massachusetts, United States
19 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
20 Massachusetts General Hospital, Boston, Massachusetts, United States
21 Massachusetts General Hospital, Boston, Massachusetts, United States
22 Massachusetts General Hospital, Boston, Massachusetts, United States
23 Massachusetts General Hospital, Boston, Massachusetts, United States
24 Massachusetts General Hospital, Boston, Massachusetts, United States
25 Massachusetts General Hospital, Boston, Massachusetts, United States
26 Massachusetts General Hospital, Boston, Massachusetts, United States
27 Massachusetts General Hospital, Boston, Massachusetts, United States
28 Massachusetts General Hospital, Boston, Massachusetts, United States
29 Massachusetts General Hospital, Boston, Massachusetts, United States
30 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
31 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
32 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
33 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
34 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
35 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
36 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
37 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
38 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
39 Massachusetts General Hospital, Boston, Massachusetts, United States
40 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ABSTRACT
Introduction: In Waldenström Macroglobulinemia (WM), attainment of a Very Good Partial Response (VGPR) or better is associated with improved progression-free survival (PFS). Bendamustine and Rituximab (BR) is highly active but conventionally requires 6 cycles though cumulative alkylator exposure carries long-term risks, including secondary malignancies and acquisition of tumor associated double hit TP53 alterations associated with inferior survival. Bruton tyrosine kinase inhibitor (BTKi) monotherapy requires indefinite treatment duration. BTKi responses are adversely impacted by the presence of CXCR4 mutations, whilst BR may overcome this adverse genomic effect. Combining BR and BTKi may therefore deepen responses across MYD88 and CXCR4 genotypes and permit a fixed duration therapeutic approach for treatment-naïve WM. Moreover, use of 4 cycles of Bendamustine may offer similar outcomes as 6 cycles in WM patients. We therefore conducted the prospective clinical trial ZeBRa utilizing 4 cycles of Bendamustine and Rituximab administered concurrently with once daily zanubrutinib (320 mg) for 15 cycles.
Methods: ZeBRa is an investigator-initiated, multicenter, open-label, single-arm phase 2 study of zanubrutinib, bendamustine, and rituximab (ZBR) in symptomatic, previously untreated WM at five US sites in the WM-NET network (NCT06561347). A total of 65 patients will be enrolled. Patients meeting IWWM2 criteria for diagnosis and treatment were eligible, and all patients regardless of MYD88, CXCR4, or TP53 mutation status were included. Zanubrutinib was administered once daily (320 mg) in 28-day cycles for 15 cycles. Bendamustine 90 mg/m2 IV (reduced for age 70 or older or creatinine clearance 30-50 mL/min) was given days 1-2 of cycles 1-4, with rituximab day 1 of cycles 1-4. MYD88, CXCR4, and TP53 were genotyped centrally. The primary endpoint was the proportion achieving VGPR or better by IWWM-11 criteria; secondary endpoints included major (MRR) and overall response rate (ORR), response by genotype, PFS, overall survival, and safety.
Results: 56 participants were enrolled as of the cutoff of June 30, 2026, with 52 subjects with >1 evaluable response assessments. Baseline characteristics were as follows: Median age: 71 years (range, 42-87); BM involvement: 50%; serum IgM: 3,006 mg/dL; and hemoglobin: 10.6 g/dL. MYD88L265P was detected in 96%, CXCR4 mutations in 34%, and TP53 mutations 12.7%. Median follow-up was 7.5 months by reverse Kaplan-Meier methodology (95% CI, 4.8-9.9; observed range, 1.0-17.5).
Responses for evaluable patients were as follows: Complete Response (CR, 7.7% [4/52]); Very Good Partial Response (VGPR, 36.5% [19/52]); Partial Response (PR, 40.4% [21/52]); Minor Response (MR, 11.5% [6/52]), and Stable Disease (SD, 3.8% [2/52]). The CR/VGPR rate was 44.2% (95% CI, 30.5-58.7), MRR (PR or better) was 84.6% (95% CI, 71.9-93.1), and the ORR (MR or better) was 96.2% (95% CI, 86.8-99.5). Among those with mutated MYD88, the CR/VGPR rate was 43.8% (14/32) and 50% (9/18) for CXCR4 wild-type and CXCR4 mutated patients, respectively. CR/VGPR rates were 42.9% (3/7) and 46.3% (19/41) in TP53-mutated patients and TP53-not-mutated patients respectively.
Treatment was well tolerated with no unexpected toxicities. Grade >3 adverse events occurred in 40% (22/55), with Grade >3 reversible neutropenia in 18.2% (10/55). Febrile neutropenia occurred in 1.8% (1/55) and Grade >3 infection in 16.4% (9/55). Growth support with granulocyte colony stimulating factor was permitted. Following 2 cases of herpes zoster, antiviral prophylaxis was required by protocol amendment with no subsequent cases observed.
Conclusion: The fixed duration regimen ZBR showed high ORR and MRR in symptomatic, treatment naive WM patients, with attainment of CR/VGPR in 44% of response evaluable participants. Importantly, CR/VGPR rates were not impacted by the presence of CXCR4 or TP53 mutations, subgroups historically associated with inferior response outcomes on BTK-inhibitors alone. Follow-up is ongoing to characterize response durability, PFS, overall survival, and safety. Our initial findings support the continued investigation of ZBR in symptomatic, treatment naïve WM patients.
DISCLOSURES
Andrew Branagan, MD, PhD: No relevant conflicts of interest to declare.